Marginal zone dural lymphoma: The Memorial Sloan Kettering Cancer Center and University of Miami experiences Journal Article


Authors: de la Fuente, M. I.; Haggiagi, A.; Moul, A.; Young, R. J.; Sidani, C.; Markoe, A.; Vega, F.; DeAngelis, L. M.; Lossos, I. S.
Article Title: Marginal zone dural lymphoma: The Memorial Sloan Kettering Cancer Center and University of Miami experiences
Abstract: Dural lymphoma (DL) is a rare type of primary CNS lymphoma arising from the dura mater. The optimal treatment is uncertain. A retrospective review was performed on 26 DL patients. Seventeen patients underwent resection and nine had a biopsy. Twenty three patients could be assessed for a response to treatment after surgery. Thirteen received focal radiotherapy (RT), six whole brain RT (WBRT), three chemotherapy alone and one chemotherapy followed by WBRT. Twenty two achieved complete response (CR) and one a partial response (PR). Four patients relapsed (two local and two systemic). Median follow up was 64 months, with median progression free survival (PFS) and OS not reached. Three year PFS was 89% (95% CI 0.64–0.97). All patients are alive at last follow-up, demonstrating that DL is an indolent tumor with long survival. CR is achievable with focal therapy in the majority of cases, but there is a risk for relapses and long-term follow-up is recommended. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: primary central nervous system lymphoma; marginal zone lymphoma; dural lymphoma; focal radiotherapy
Journal Title: Leukemia and Lymphoma
Volume: 58
Issue: 4
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2017-01-01
Start Page: 882
End Page: 888
Language: English
DOI: 10.1080/10428194.2016.1218006
PROVIDER: scopus
PUBMED: 27649904
PMCID: PMC5576515
DOI/URL:
Notes: Article -- Export Date: 2 February 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Robert J Young
    108 Young